Aquestive Therapeutics (AQST) Depreciation & Amortization (CF) (2017 - 2026)

Aquestive Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $113000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 18.71% year-over-year to $113000.0; the TTM figure through Mar 2026 stood at $522000.0 (down 19.69% YoY), while the FY2025 annual figure was $548000.0, down 23.68% from the prior year.
• Depreciation & Amortization (CF) was $113000.0 for Q1 2026 at Aquestive Therapeutics, down from $130000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $727000.0 in Q1 2022 to a low of $113000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $300647.1 across 5 years, with a median of $207000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) climbed 17.63% in 2023, then slumped 68.52% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $397000.0 in 2022, then grew by 17.63% to $467000.0 in 2023, then slumped by 68.52% to $147000.0 in 2024, then slipped by 11.56% to $130000.0 in 2025, then dropped by 13.08% to $113000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $113000.0 (Q1 2026), $130000.0 (Q4 2025), and $139000.0 (Q3 2025), per Business Quant data.